Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease
- Conditions
- Type 2 DiabetesChronic Obstructive Pulmonary Disease
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: L. salivarius AP-32 and L. reuteri GL-104Dietary Supplement: L. reuteri GL-104
- Registration Number
- NCT05492448
- Lead Sponsor
- Glac Biotech Co., Ltd
- Brief Summary
This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar levels significantly in comparison with placebo, and observe if the reduced lung function could be recovered in patients with type 2 diabetes (T2DM) and chronic obstructive pulmonary disease (COPD) simultaneously.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 120
- Subjects are between 50-85 years old, and clinical diagnosis of T2DM (HbA1c ≥ 6.5% or fasting plasma glucose ≥ 126 mg/dL or oral glucose tolerance test 2-hour plasma glucose ≥ 200 mg/dL).
- Patients with stable pulmonary obstruction (pulmonary function FEV1/FVC <0.7) with symptoms of pulmonary obstruction.
- Subjects can cooperate with the collection of experimental specimens and return for regular visits.
- The patient or family members have signed the informed consent form.
- The patient must receive adjuvant treatment with probiotic for 12 weeks.
- The patient or caregiver is unable to follow the physician's instructions for the trial, including the completed symptom assessment form and compliance with medication.
- The patient has a history of related allergic reactions, or the use of other highly sensitive or contraindicated drugs (Allergy to antibiotics or antipyretics).
- The patient have taken oral immunosuppressive drugs, intravenous steroids or T cell inhibitor ointments within the past 2 weeks.
- The patient has consumed probiotic-related products (including drops, lozenges, capsules, powder and yogurt) within the past 1 month.
- The patient received high doses of steroids within the past 1 month.
- The patient with active infection or severe pulmonary disease (eg, tuberculosis, bronchiectasis, or fibrosis).
- The patient is receiving treatment for a major disease or congenital disease.
- The patient is not suitable to participate in the trial as assessed by the professional physician.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - L. salivarius AP-32 and L. reuteri GL-104 L. salivarius AP-32 and L. reuteri GL-104 - L. reuteri GL-104 L. reuteri GL-104 -
- Primary Outcome Measures
Name Time Method Changes in concentration of glycated hemoglobin (HbA1c). Before and after 4-, 12-week intervention. Changes in concentration of HbA1c were assessed before and after 4-, 12-week intervention.
Changes in ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). Before and after 4-, 12-week intervention. Changes in ratio of FEV1/FVC were assessed by bronchodilator test before and after 4-, 12-week intervention.
- Secondary Outcome Measures
Name Time Method Changes in scores of modified medical research council (mMRC). Before and after 4-, 12-week intervention. Changes in scores of mMRC were assessed before and after 4-, 12-week intervention. The minimum score is 0 and the maximum score is 4. A higher score means more difficult breathing.
Changes in scores of COPD assessment test (CAT). Before and after 4-, 12-week intervention. Changes in scores of CAT were assessed before and after 4-, 12-week intervention. The minimum score is 0 and the maximum score is 40. A higher score means more seriously affect life.
Changes of the composition in gut microbiota. Before and after 12-week intervention. Changes of the composition in gut microbiota were analyzed by next-generation sequencing (NGS) before and after 12-week intervention.
Changes in concentration of immune cytokines. Before and after 4-, 12-week intervention. Changes in concentration of immune cytokines were assessed before and after 4-, 12-week intervention.
Changes of the composition in lower respiratory tract microbiota. Before and after 12-week intervention. Changes of the composition in lower respiratory tract microbiota were analyzed by next-generation sequencing (NGS) before and after 12-week intervention.
Changes of concentration in short-chain fatty acid (SCFA) on plasma. Before and after 12-week intervention. Changes of concentration in SCFA on plasma were analyzed by gas chromatography-mass spectrometry before and after 12-week intervention.
Changes of concentration in short-chain fatty acid (SCFA) on stool. Before and after 12-week intervention. Changes of concentration in SCFA on stool were analyzed by gas chromatography-mass spectrometry before and after 12-week intervention.
Changes in scores of modified Bristol stool form scale. Before and after 4-, 12-week intervention. Changes in scores of modified Bristol stool form scale were assessed before and after 4-, 12-week intervention. The questionnaire included the stool form \[1 = very hard (small hard lumps), 2 = hard stool (hard sausage shape), 3 = normal stool (sausage to banana shape), 4 = soft stool, 5 = muddy stool, 6 = watery stool\], ease of defecation (1 = difficult, 2 = easy, 3 = very easy) and abdominal symptoms \[frequency of upper abdominal pain, lower abdominal pain, borborygmus, and flatulence (1 = frequent, 2 = occasional, 3 = almost never)\].
Changes in concentration of fasting blood sugar. Before and after 4-, 12-week intervention. Changes in concentration of fasting blood sugar were assessed before and after 4-, 12-week intervention.
Trial Locations
- Locations (1)
Glac Biotech Co., Ltd.
🇨🇳Tainan City, Taiwan